Abstract: Objective The aim of this clinical trial was to investigate the preoperative doxorubicin magnetic fluid targeted chemotherapy before microwave ablation (MWA) in the treatment of patients with primary liver cancer (PLC). Methods 65 patients with PLC were encountered in our hospital between January 2018 and January 2021, and were randomly divided into observation (n=33) and control group (n=32). The patients in the control group was treated with percutaneous MWA, and those in the observation group was treated with preoperative doxorubicin magnetic fluid targeted chemotherapy before MWA. The clinical efficacy was evaluated by mRECIST. Serum carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), fucosidase (AFU) and alpha-fetoprotein (AFP) levels were detected by ELISA. The percentages of peripheral blood of CD3⁺, CD4⁺ and CD8⁺ cells were detected by flow cytometry. Results The total effective rate in the observation group at one-month evaluation was 87.9%, much higher than 65.6%(P＜0.05) in the control; at the end of one month after MWA, serum CA19-9, CEA, AFU and AFP levels in the observation group were (23.5±4.7)U/L,(9.3±2.1)μg/mL, (36.4±6.9)U/L and (78.5±10.2)ng/mL, all significantly lower than [(31.2±5.1)U/L, (12.6±3.5)μg/mL,(45.1±10.2)U/L and (103.6±17.1)ng/mL, respectively, P＜0.05] in the control; the percentages of peripheral blood CD3⁺ and CD4⁺ cells as well as the ratio of CD4⁺/CD8⁺ cells in the observation group were (70.5±9.1)%, (39.8±4.7)% and (1.6±0.2), all significantly higher than [(61.1±8.8)%, (31.9±4.4)% and (1.4±0.1), respectively, P＜0.05] in the control. Conclusion The procedure of adriamycin magnetic fluid targeted chemotherapy before MWA in dealing with patients with PLC could promote the short-term efficacy, which might be related to the regulation of immune functions.

Key words: Hepatoma, Magnetic guide carrier, Adriamycin, Microwave ablation, Therapy